Cargando…
White paper by the Society for CSF Analysis and Clinical Neurochemistry: Overcoming barriers in biomarker development and clinical translation
Body fluid biomarkers have great potential for different clinical purposes, including diagnosis, prognosis, patient stratification and treatment effect monitoring. This is exemplified by current use of several excellent biomarkers, such as the Alzheimer’s disease cerebrospinal fluid (CSF) biomarkers...
Autores principales: | Teunissen, Charlotte E., Otto, Markus, Engelborghs, Sebastiaan, Herukka, Sanna-Kaisa, Lehmann, Sylvain, Lewczuk, Piotr, Lleó, Alberto, Perret-Liaudet, Armand, Tumani, Hayrettin, Turner, Martin R., Verbeek, Marcel M., Wiltfang, Jens, Zetterberg, Henrik, Parnetti, Lucilla, Blennow, Kaj |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5855933/ https://www.ncbi.nlm.nih.gov/pubmed/29544527 http://dx.doi.org/10.1186/s13195-018-0359-x |
Ejemplares similares
-
Should CSF Biomarkers Support a Routine Analysis for Early Diagnosis of Alzheimer's Disease?
por: Parnetti, Lucilla, et al.
Publicado: (2010) -
A Practical Guide to Immunoassay Method Validation
por: Andreasson, Ulf, et al.
Publicado: (2015) -
Neuroinflammation and Alzheimer’s Disease: A Machine Learning Approach to CSF Proteomics
por: Gaetani, Lorenzo, et al.
Publicado: (2021) -
Differential Sialylation of Serpin A1 in the Early Diagnosis of Parkinson’s Disease Dementia
por: Jesse, Sarah, et al.
Publicado: (2012) -
No diurnal variation of classical and candidate biomarkers of Alzheimer’s disease in CSF
por: Cicognola, Claudia, et al.
Publicado: (2016)